Nerandomilast

Nerandomilast is a newly FDA-approved oral medication for the treatment of idiopathic pulmonary fibrosis (IPF), developed by Boehringer Ingelheim and marketed as Jascayd. It is the first major new therapy for IPF granted approval in over a decade, addressing a significant unmet need in managing this severe and progressive lung disease. It is grouped under the following drug class(es): PDE4 inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include (1-(((5R)-2-(4-(5-chloropyrimidin-2-yl)piperidin-1-yl)-5-oxo-6, 7-dihydrothieno(3, 2-d)pyrimidin-4-yl)amino)cyclobutyl)methanol, (R)-2-(4-(5-Chloropyrimidin-2-yl)piperidin-1-yl)-4-((1-(hydroxymethyl)cyclobutyl)amino)-6, 7-dihydrothieno[3 and 2-d]pyrimidine 5-oxide. Its PubChem CID is 166177189.

CAS No 1423719-30-5
Molecular Formula C20H25ClN6O2S
Molecular Weight 449.0 g/mol
Synonyms [1-[[(5R)-2-[4-(5-chloropyrimidin-2-yl)piperidin-1-yl]-5-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-4-yl]amino]cyclobutyl]methanol

Frequently Asked Questions